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Abstract
Background: Xpert MTB/RIF is approved for use in tuberculosis (TB) and rifampicin-resistance diagnosis. However, data are
limited on the impact of Xpert under routine conditions in settings with high TB burden.
Methods and Findings: A pragmatic prospective cluster-randomised trial of Xpert for all individuals with presumptive
(symptomatic) TB compared to the routine diagnostic algorithm of sputum microscopy and limited use of culture was
conducted in a large TB/HIV primary care clinic. The primary outcome was the proportion of bacteriologically confirmed TB
cases not initiating TB treatment by 3 mo after presentation. Secondary outcomes included time to TB treatment and
mortality. Unblinded randomisation occurred on a weekly basis. Xpert and smear microscopy were performed on site.
Analysis was both by intention to treat (ITT) and per protocol. Between 7 September 2010 and 28 October 2011, 1,985
participants were assigned to the Xpert (n= 982) and routine (n= 1,003) diagnostic algorithms (ITT analysis); 882 received
Xpert and 1,063 routine (per protocol analysis). 13% (32/257) of individuals with bacteriologically confirmed TB (smear,
culture, or Xpert) did not initiate treatment by 3 mo after presentation in the Xpert arm, compared to 25% (41/167) in the
routine arm (ITT analysis, risk ratio 0.51, 95% CI 0.33–0.77, p= 0.0052). The yield of bacteriologically confirmed TB cases
among patients with presumptive TB was 17% (167/1,003) with routine diagnosis and 26% (257/982) with Xpert diagnosis
(ITT analysis, risk ratio 1.57, 95% CI 1.32–1.87, p,0.001). This difference in diagnosis rates resulted in a higher rate of
treatment initiation in the Xpert arm: 23% (229/1,003) and 28% (277/982) in the routine and Xpert arms, respectively (ITT
analysis, risk ratio 1.24, 95% CI 1.06–1.44, p= 0.013). Time to treatment initiation was improved overall (ITT analysis, hazard
ratio 0.76, 95% CI 0.63–0.92, p= 0.005) and among HIV-infected participants (ITT analysis, hazard ratio 0.67, 95% CI 0.53–0.85,
p= 0.001). There was no difference in 6-mo mortality with Xpert versus routine diagnosis. Study limitations included
incorrect intervention allocation for a high proportion of participants and that the study was conducted in a single clinic.
Conclusions: These data suggest that in this routine primary care setting, use of Xpert to diagnose TB increased the number
of individuals with bacteriologically confirmed TB who were treated by 3 mo and reduced time to treatment initiation,
particularly among HIV-infected participants.
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Introduction
Despite intensified tuberculosis (TB) control efforts over the last
two decades, 8.6 million new TB cases were estimated to have
emerged in 2012, resulting in at least 1.3 million deaths [1]. In the
absence of dramatic improvements in socio-economic status
among individuals at risk for TB, TB control rests on diagnosing
prevalent and infectious TB cases, instituting appropriate treat-
ment, and thereby reducing ongoing transmission. Until recently,
the mainstay of TB diagnosis in settings with high TB burden was
sputum smear microscopy. Smear microscopy, while cheap and
easy to implement, has low sensitivity and will therefore detect
only TB cases with substantial bacterial load and advanced
disease. Sputum culture, while considered the gold standard for
pulmonary TB diagnosis, is often available only at the level of a
reference laboratory and is most often too slow to be able to guide
therapy. This is particularly the case in settings with high HIV
prevalence, where the mortality associated with late or inaccurate
diagnosis of TB is high [2]. In order to prevent transmission and
improve outcomes for individual patients, a diagnostic test that
detects TB disease at lower bacterial burdens and provides rapid
results in order for treatment to be instituted is needed.
The Xpert MTB/RIF test is a real-time PCR assay for
simultaneous detection of Mycobacterium tuberculosis and rifampi-
cin resistance [3]. Based on validation and feasibility data [4], the
Xpert test was recommended for use in TB diagnosis by the World
Health Organization in late 2010. Since then, through preferential
pricing for low- and middle-income countries, a number of
countries have attempted to scale up access to Xpert MTB/RIF
in national TB control programmes [5]. South Africa has
committed to provide access to Xpert testing for all individuals
with presumptive TB through a staged roll-out strategy nationwide.
While significant data exist on the specificity and sensitivity of
Xpert testing [6], there are limited data available on the impact of
implementing Xpert on health outcomes in routine programmatic
settings [7,8]. As a result, there remains controversy as to how
Xpert should be implemented in different health systems and who
should be tested. We aimed to assess the impact of using Xpert for
TB diagnosis on yield of TB cases and the timing of TB treatment
initiation in a large primary health care clinic, through a
pragmatic randomised controlled trial.
Methods
Ethics Statement
The study protocol was approved by the University of Cape
Town Human Research Ethics Committee (366/2009), and
complies with the principles outlined in the Declaration of
Helsinki.
Study Design and Pre-Specified Outcomes
This was a prospective cluster-randomised trial of Xpert
implementation compared to the pre-existing routine diagnostic
algorithm of smear, culture, and drug susceptibility testing (DST)
in a primary care clinic in Khayelitsha, Cape Town, South Africa.
This trial, an extension of an earlier validation and feasibility study
[4], was registered in the Pan African Clinical Trials Registry
(PACTR201010000255244) 1 mo after the study started based on
the realisation of the importance of trial registration.
The pre-specified primary outcome was the proportion of
bacteriologically confirmed TB cases that had not initiated
appropriate treatment by 2 mo after enrolment. For analysis, the
denominator for this outcome included all participants diagnosed
with bacteriologically confirmed TB (smear, culture, or Xpert)
during the 2-mo period after enrolment. As there were a number
of TB cases diagnosed late in this period, the time period to assess
treatment initiation was extended (at the time of data analysis) to
3 mo after enrolment.
Secondary outcomes were time to diagnosis, time to TB
treatment, all-cause mortality, and the number of clinic visits prior
to appropriate TB treatment. Two of these secondary outcomes,
time to diagnosis and the number of clinic visits prior to treatment,
are not reported on here, as data were of poor quality and
inconsistently available. Analyses of TB treatment initiation by
HIV status, TB treatment outcomes, and yield of rifampicin-
resistant TB were conducted post hoc.
Study Site
The study was conducted in a large primary health care clinic in
Khayelitsha, Cape Town. Khayelitsha is a peri-urban township with
an estimated population of 400,000 [9]. Antenatal HIV prevalence is
estimated at 33%, and TB case notification at 1,200/100,000 [10].
Ubuntu Clinic is a specialised primary care clinic providing
integrated HIV and TB services. In 2011, 1,443 individuals received
TB treatment at Ubuntu Clinic, and by December 2011, 6,296
clients were receiving antiretroviral HIV treatment through the clinic.
In September 2009, a small decentralised laboratory providing
sputum smear microscopy, staffed by one laboratory technician, was
established on site at Ubuntu Clinic.
Study Intervention and Randomisation
All adults, aged 18 y and over, presenting at Ubuntu Clinic with
presumptive TB were included in the study. The definition of
presumptive TB employed in Cape Town includes any of the
following: cough of 2 wk or more, weight loss, drenching night
sweats, fever of 2 wk or more, chest pain on breathing, or blood-
stained sputum. Individuals already receiving anti-TB treatment
for 3 d or more were excluded. The study was designed as a
pragmatic trial, in order to provide minimal disruption and to
reflect normal routine clinical practice. Clinic staff and investiga-
tors were unblinded to the intervention. Individual informed
consent at study inclusion was waived for this study based on the
pragmatic nature of the trial. Randomisation occurred on a weekly
basis in order to allow efficient laboratory functioning and use of
resources. Each week was randomly allocated as either Xpert or
routine diagnostic testing, with the schedule generated prior to the
study (using Random.org) by the principal investigator.
Patients in both study arms gave two sputum samples as per
routine practice in Cape Town. Diagnostic testing for the sputum
samples in each arm is described in Figure 1. Diagnosis in the
routine arm was based on the policy for diagnostic testing for
individuals with presumptive TB in the City of Cape Town.
Briefly, diagnosis was primarily based on smear, with culture and
DST for those considered at high risk of drug-resistant TB, and
where clinically indicated (predominantly among HIV-infected
individuals). Individuals considered to be at high risk for drug-
resistant TB included those previously treated for TB, health care
workers, and those with any prison contact.
Participants enrolled during each designated Xpert week had
Xpert requested on the routine laboratory request forms. This was
done by trained routine health care staff or one staff member
employed specifically for the study and located in the same clinic
room in which individuals with presumptive TB were seen. All
positive Xpert results were considered as positive for M.
tuberculosis and requiring treatment. However, at the time of this
study, rifampicin resistance diagnosed by Xpert required subse-
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quent confirmation with sputum culture and DST before second-
line treatment was initiated.
Laboratory Methods
Two four-cartridge-capacity GeneXpert machines were installed
in the on-site clinic laboratory. The Xpert MTB/RIF test was done
on raw sputum samples, with an automated readout provided to the
user, as described elsewhere [3]. Indeterminate Xpert results were
repeated if further sputum was available. For sputum smear
microscopy, in both the on-site and central laboratories, a
concentrated auramine smear was prepared and examined under
magnification (5006) using a fluorescent microscope and graded
according to International Union Against Tuberculosis and Lung
Disease guidelines [11]. External quality control for smear
microscopy was conducted quarterly. In the central laboratory, a
0.5-ml portion of the sediment was cultured in mycobacterial
growth indicator tubes with PANTA and OADC using the
BACTEC MGIT 960 system (BD Diagnostics, Sparks, Maryland).
Susceptibility to rifampicin was confirmed using the line probe assay
MTBDRplus (Hain Lifescience, Nehren, Germany). DST was
performed on NaOH-treated pellets for smear-positive sputum and
on cultured isolates for smear-negative sputum.
Participant Follow-Up
Participants were followed up at two time points after study
inclusion: at 2–3 mo to assess whether TB treatment was initiated,
and at 6 mo to assess mortality. All participants were initially
tracked through the clinic TB diagnosis and TB treatment registers
to determine status and outcomes. For participants with a negative
TB diagnosis and those with a positive diagnosis who were not
started on treatment, follow-up consisted of a home visit, with
subsequent phone contact if the participant could not be contacted
through the home visit. Verbal informed consent was required for
collection of follow-up data via telephone contact, and written
consent for direct contact with participants.
Additionally, all participants were tracked through district
(Cape Town metropole) TB and HIV treatment registers to
ascertain whether TB treatment was initiated elsewhere. These
registers were also used to ascertain TB treatment outcomes.
Participants who could not be followed directly at either of the two
follow-up time points were also tracked through regional and
national death registries via name and civil identification number,
respectively. Linkage with the national death registry in South
Africa has been previously shown to have high levels of sensitivity
and specificity for Khayelitsha [12].
Sample Size and Statistical Analysis
The sample size was calculated based on an expected higher yield
of bacteriologically confirmed TB cases of 20% to 30% among
individuals with presumptive TB in the Xpert arm compared to the
routine arm (80% power and one-sided significance p,0.05). We
assumed 40 patients would be seen per week and assumed a weak
intra-cluster correlation coefficient of 0.05, resulting in a design
effect of 3 and a required sample size of 882 per study arm.
Bacteriological confirmation of TB was defined as a positive
Xpert result for M. tuberculosis, M. tuberculosis isolated on liquid
culture, or positive smear microscopy regardless of grade.
Mortality was assessed up to 6 mo after study inclusion. TB
treatment outcomes were defined using World Health Organiza-
tion guidelines [13], with treatment success defined as either cure
or treatment completion in the absence of treatment failure.
Mortality was defined as death regardless of cause.
The proportion of participants initiating treatment and time to TB
treatment initiation were calculated from the date of participant
enrolment, with data censored at death. As ascertainment of TB
treatment initiation or not by 3 mowas assumed to be complete, data
were not censored for loss to follow-up in Kaplan Meier analyses.
Similarly, ascertainment of death was assumed to be complete at
6 mo after enrolment.
Analyses were based on intention to treat (ITT), regardless of
which diagnostic tests were performed, and per protocol, based on
which tests were actually conducted. Response rates and category
membership were compared using design-based F-tests to take into
account the cluster sampling. Kaplan Meier analyses were used to
assess the proportion of participants initiating TB treatment over
time, with comparisons using the logrank test.
Results
Study Population and Randomisation
In total, 1,985 individuals with presumptive TB were included
in the study over the 60 wk from September 7, 2010, to October
Figure 1. Diagnostic testing algorithm for each study arm.
doi:10.1371/journal.pmed.1001760.g001
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28, 2011. The study was interrupted for a total of 9 wk during the
study period because of technical or safety issues in the on-site
laboratory and sick leave of laboratory staff. During these periods,
no participants were recruited, and routine practice was followed.
During the study weeks, the intervention was not always
correctly assigned. During 23 of the 51 wk of the study, more than
10% of participants in that week received the incorrect interven-
tion, most commonly routine testing instead of Xpert (participant
flow diagram, Figure 2). A review of data and processes suggests
that a number of issues contributed to this. The most common
cause of incorrect intervention assignment was a failure to request
Xpert testing during Xpert weeks, generally resulting from the
absence of the specific study health care worker for short periods of
time in the clinic consulting room, whereby clinic staff requested
sputum tests as per routine. This occurred despite extensive
training, and was unfortunately not detected until near the study
end. In addition, at the start of some weeks, both routine and study
staff continued the intervention that was in place the previous
week and this was not corrected until sometime during the week.
The ITT analysis included all 1,985 participants (982 in the
Xpert arm and 1,003 in the routine arm), while the per protocol
analysis, based on whether participants received Xpert or not,
excluded participants where no sputum sample was available,
yielding 1,945 participants in total (882 in the Xpert arm and
1,063 in the routine arm). There were no differences in the
proportions of individuals with previous TB treatment, known
HIV status, and HIV positivity between arms in both analyses,
and arms were similar with regard to age and sex (Table 1),
suggesting that those participants who did not receive the correct
intervention were not different than those who did.
TB Diagnostic Results
In the ITT analysis, 98% (964/982) of participants in the Xpert
arm and 98% (981/1,003) of participants in the routine arm
received any diagnostic TB testing on sputum (Table 2). The
remaining participants either failed to submit any sputum samples,
or samples could not be tested, most commonly because of leakage
or inadequate specimen labelling.
Across both analyses, the proportion of patients whose
specimens underwent culture in both arms was similar, as was
the proportion of these with positive culture (Table 2). The most
common indication for culture was previous TB treatment, with
very few participants classified as being at high risk for multidrug-
resistant TB (MDR-TB) for other reasons (Table 3). The
remaining participants for whom culture was requested were
primarily HIV-infected participants with a negative sputum smear
(ITT analysis; Table 3). In the ITT analysis, 24% (199/823) of all
Xpert tests were positive, while only 10% (91/958) of participants
in the routine arm were sputum-smear-positive (predominantly
sputum smears conducted in the on-site laboratory). Similar
percentages were seen in the per protocol analysis (Table 2). There
was a significantly higher rate of bacteriologically confirmed TB
disease (by either sputum smear, culture, or Xpert) in the Xpert
arm than in the routine arm: 17% (167/1,003) in the routine arm
and 26% (257/982) in the Xpert arm (ITT analysis, risk ratio 1.57,
95% CI 1.32–1.87, p,0.001), with 18% (189/1,063) and 27%
(235/882), respectively, in the per protocol analysis (risk ratio 1.50,
95% CI 1.27–1.78, p,0.001) (Table 2).
Among the 211 participants with a positive Xpert result, smear
results were available for 95.7% (202/211), but only 28.7% (58/
202) of these were sputum-smear-positive. Culture was performed
for 96 participants with positive Xpert results, among whom 82
(85.4%) were culture-positive, three had contaminated culture,
and 11 were culture-negative. Among individuals with positive
Xpert results, there was no difference in the proportion that were
culture-negative between those who reported previous TB
treatment and those with no previous TB treatment (risk ratio
1.01, 95% CI 0.32–3.2, p=0.99).
Primary Outcome
Among patients with bacteriologically confirmed disease (smear,
culture, or Xpert), 13% (32/257) in the Xpert arm had not
initiated treatment by 3 mo after enrolment, compared to 25%
(41/167) in the routine arm (ITT analysis, risk ratio 0.51, 95% CI
0.33–0.77, p=0.0052).
TB Treatment Initiation and Time to Treatment
In the Xpert arm, TB treatment was initiated within 3 mo for a
significantly greater proportion of participants, regardless of
bacteriological confirmation, in both the ITT and per protocol
analyses (Table 4). In the ITT analysis, 28% (277/982) of
participants in the Xpert arm started treatment, compared to
23% (229/1,003) in the routine arm (risk ratio 1.24, 95% CI 1.06–
1.44, p=0.013). This increased treatment initiation was due
primarily to increased treatment initiation among HIV-infected
participants, with no significant difference among HIV-negative
participants (Table 4). In the Xpert arm, the majority of
participants starting treatment had bacteriologically confirmed
TB, and the proportion of patients initiating TB treatment without
bacteriological confirmation of pulmonary TB, was approximately
halved overall (ITT analysis; Table 5).
In addition to increased numbers starting treatment, TB
treatment was also initiated more rapidly in the Xpert arm: a
median of 4 d after enrolment in the Xpert arm in both analyses
compared to 8 and 9 d in the routine arm in the ITT and per
protocol analyses, respectively (Table 4). In contrast to the results
by HIV status for the proportion starting treatment, reduced delay
was more notable among HIV-negative participants than among
HIV-infected participants (Table 4). These dual benefits of
increased treatment initiation and reduced delay are shown in a
time-to-treatment analysis (Kaplan Meier) for all participants
(Figure 3) and by HIV status (Figure 4). Time to treatment
initiation (Kaplan Meier) was significantly improved overall with
Xpert compared to routine testing (ITT analysis, hazard ratio
0.76, 95% CI 0.63–0.92, p=0.005) and among HIV-infected
participants (ITT analysis, hazard ratio 0.67, 95% CI 0.53–0.85,
p=0.001) (Figures 3 and 4A). Although TB treatment was
initiated more rapidly among HIV-negative participants, the
proportion starting treatment by 3 mo was similar between Xpert
and routine arms (ITT analysis, hazard ratio 0.86, 95% CI 0.60–
1.22, p=0.39) (Figure 4B).
Rifampicin Resistance
There was no difference in the proportion of confirmed
rifampicin-resistant TB diagnosed in the two arms in the ITT
analysis: 1.1% (11/982) in the Xpert arm and 0.8% (8/1,003) in
the routine arm (risk ratio 1.40, 95% CI 0.57–3.48, p=0.4219).
Among the 424 bacteriologically confirmed TB cases across both
arms, 19 (4.5%, 95% CI 2.8%–6.8%) were confirmed to be
rifampicin-resistant.
Of the eight cases found to be Xpert-positive and rifampicin-
resistant in the Xpert arm, only five of these were confirmed on
culture and line probe assay. Of the remaining three cases, two
were deemed rifampicin-susceptible using the line probe assay,
and no culture could be obtained for the remaining case. A
further two Xpert-negative cases in the Xpert arm were found
to be rifampicin-resistant after a positive culture, while two cases
were tested as Xpert-positive with rifampicin susceptibility, but
Impact of Xpert for TB Diagnosis in South Africa
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Figure 2. Participant flow diagram.
doi:10.1371/journal.pmed.1001760.g002
Table 1. Clinical and demographic characteristics of participants by study arm for both the ITT and per protocol analyses.
Characteristic ITT Analysis Per Protocol Analysis
Xpert Routine Xpert Routine
N 982 1,003 882 1,063
Male 543 (55.3%) 542 (54.0%) 486 (55.1%) 584 (54.9%)
Age
18–30 y 228 (23.2%) 266 (26.5%) 216 (24.5%) 264 (24.8%)
31–40 y 343 (34.9%) 310 (30.9%) 305 (34.6%) 340 (32.0%)
41–50 y 208 (21.2%) 221 (22.0%) 180 (20.4%) 242 (22.8%)
51+ y 203 (20.7%) 205 (20.5%) 181 (20.5%) 316 (20.3%)
HIV status known 815 (83.0%) 810 (80.8%) 723 (82.0%) 975 (82.3%)
HIV positive (percent of known) 481 (59.0%) 484 (59.8%) 429 (59.3%) 525 (60.0%)
HIV negative 334 326 294 350
Previous TB treatment 382 (38.9%) 363 (36.2%) 327 (37.1%) 409 (38.5%)
Data are n (percent).
doi:10.1371/journal.pmed.1001760.t001
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were diagnosed as rifampicin-resistant on culture and line probe
assay.
TB Treatment Outcomes and Survival
Among participants initiating treatment (excluding those
diagnosed with confirmed rifampicin-resistant TB), TB treat-
ment outcomes were similar, both overall and among HIV-
infected participants in the ITT analysis (Table 6). However,
given the difference in the proportion of participants initiating
treatment, the proportion of participants with a successful
treatment outcome overall was significantly greater in the
Xpert arm than in the routine arm: 21.9% (215/982)
compared to 17.5% (176/1,003), respectively (risk ratio 1.25,
95% CI 1.04–1.49, p= 0.0319). This effect was greater for
HIV-infected participants: 26.8% (129/481) of participants in
the Xpert arm were successfully treated, compared to 19.6%
(95/484) in the routine arm (risk ratio 1.37, 95% CI 1.08–1.73,
p= 0.0119).
Within 6 mo from presentation, 3.4% (33/982) of participants
died in the Xpert arm and 3.8% (38/1,003) in the routine arm
(ITT analysis, risk ratio 0.89, 95% CI 0.56–1.40, p=0.5178).
Among HIV-infected participants, 6-mo mortality was similar:
5.0% (24/481) in the Xpert arm and 5.0% (24/484) in the routine
arm (risk ratio 1.01, 95% CI 0.58–1.75, p=0.9789).
Table 2. Microbiological results by study arm for both the ITT and per protocol analyses.
Result ITT Analysis Per Protocol Analysis
Xpert Routine p-Value Xpert Routine p-Value
N 982 1,003 882 1,063
Sputum available 964 (98.2%) 981 (97.8%) 0.732 882 1,063
Xpert
Xpert available 823 (85.4%) 59 (6.0%) 882
Xpert negative 619 47 666
Xpert indeterminate 5 0 5
Xpert positive
(percent of Xpert available)
199 (24.2%) 12 (20.3%) 0.469 211 (23.9%)
Sputum smear microscopy
Smear available 676 (68.8%) 958 (95.5%) 571 (64.7%) 1,062 (99.9%)
Smear negative 593 867 508 951
Smear positive
(percent of smear available)
83 (12.3%) 91 (9.5%) 0.076 63 (11.0%) 111 (10.5%) 0.713
Culture
Culture available 474 (48.3%) 459 (45.8%) 0.476 418 (47.4%) 515 (48.5%) 0.493
Contaminated/lost 29 (6.1%) 29 (6.3%) 29 (6.8%) 29 (5.6%)
Non-tuberculous mycobacteria 8 2 7 3
Culture negative 318 319 281 356
Culture positive
(percent of valida culture results)
119 (27.2%) 109 (25.5%) 0.533 101(26.4%) 127 (26.3%) 0.963
Bacteriologically confirmed
TB (Xpert, smear, or culture)
257 (26.2%) 167 (16.7%) ,0.001 235 (26.6%) 189 (17.8%) ,0.001
Data are n (percent).
aExcludes cultures that are contaminated.
doi:10.1371/journal.pmed.1001760.t002
Table 3. Number and percentage of participants for whom culture was requested by indication across study arms (ITT analysis).
Indication for Culture Xpert Routine p-Value
N Culture Requested N Culture Requested
Previous TB treatment 382 350 (92%) 363 329 (91%)
Other MDR-TB risk factors 3 3 (100%) 0 0 (0%)
HIV-infected, smear-negative
(excluding previous TB treatment
and other MDR-TB risk factors)
143 72 (50%) 248 84 (34%) 0.438
Reason for culture not stated 49 46
Total culture requested 474 459
doi:10.1371/journal.pmed.1001760.t003
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Discussion
In this primary care setting with high TB and HIV
prevalence, this study demonstrates clear benefits from the
provision of Xpert MTB/RIF testing for all individuals with
presumptive TB over a diagnostic algorithm relying primarily
on smear microscopy. The proportion of individuals with
bacteriologically confirmed TB who had not initiated TB
treatment by 3 mo, the primary outcome, was significantly
lower in the Xpert arm than in the routine arm. In addition, the
proportion of participants with microbiologically confirmed TB
and the proportion initiating TB treatment were both signifi-
cantly higher in the Xpert arm. These gains were combined
with shortened times to treatment, leading to significant
improvements in overall TB treatment initiation and the
proportion of participants successfully treated for TB.
These benefits were seen despite inadequate application of the
intervention. This was a pragmatic trial aiming to provide minimal
disruption and change to normal clinic practices. However, the
pragmatic nature of the trial resulted in compromised trial
conduct. Based on a retrospective review of practices, we do not
feel that the inadequate application of the intervention was due to
any systematic biases by health care staff. There was no evidence
that Xpert was more likely to be requested for patients who might
be considered to be at higher risk of TB or MDR-TB. As there was
no significant difference between the Xpert arm and the routine
arm in the proportion of smear-negative HIV-infected participants
for whom culture was requested, this is not expected to have
Table 4. TB treatment initiation, overall and by HIV status, in the Xpert and routine arms for both the ITT and per protocol
analyses.
Treatment Initiation ITT Analysis Per Protocol Analysis
Xpert Routine p-Value Xpert Routine p-Value
All study participants, n 982 1,003 882 1,063
Start TB treatment within
3 mo, n (percent)
277 (28.2%) 229 (22.8%) 0.013 256 (29.0%) 246 (23.1%) 0.0052
Days to start treatmenta,
median (IQR)
4 (2–8) 8 (2–27) 4 (2–7) 9 (2–27)
HIV-negative
participants, n
334 326 294 350
Start TB treatment
within 3 mo, n (percent)
68 (20.4%) 60 (18.4%) 0.536 60 (20.4%) 66 (18.9%) 0.625
Days to start treatmenta,
median (IQR)
4 (2–7) 11 (3–35) 3 (1.5–6) 13 (4–35)
HIV-infected
participants (n)
481 484 429 825
Start TB treatment
within 3 mo, n (percent)
171 (35.6%) 127 (26.2%) 0.003 161 (37.5%) 135 (25.7%) ,0.001
Days to start treatmenta,
median (IQR)
4 (2–10) 8 (2–22) 4 (2–7) 8 (2–27)
aThe number of days from enrolment to the start of treatment.
IQR, interquartile range.
doi:10.1371/journal.pmed.1001760.t004
Table 5. Participants initiating TB treatment with confirmed TB (bacteriologically positive) and unconfirmed TB, overall and by HIV
status (ITT analysis).
Participants Started TB Treatment p-Value
Xpert Routine
All study participants 982 1,003
Confirmed TB 226 (23.0%) 131 (13.1%)
Unconfirmed TB 51 (5.2%) 98 (9.8%) 0.0025
HIV-negative participants 334 326
Confirmed TB 52 (15.9%) 33 (10.1%)
Unconfirmed TB 15 (4.5%) 27 (8.3%) 0.1608
HIV-infected participants 481 484
Confirmed TB 139 (28.9%) 68 (14.0%)
Unconfirmed TB 32 (6.7%) 59 (12.2%) 0.0231
Data are the number (percent) of participants who started TB treatment within 3 mo of enrolment.
doi:10.1371/journal.pmed.1001760.t005
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contributed to the higher rate of bacteriologically confirmed TB in
the Xpert arm, nor to the proportion of participants initiating TB
treatment rapidly after presentation. Overall, we feel that the
problems with application of the intervention were predominantly
because of the crossing over of the intervention using the weekly
randomisation schedule and the difficulties of trying to introduce
additional steps into a well-established clinical process.
Similarly, the intervention was unblinded, and this is also a
limitation of the study design chosen. The study also included only
participants who gave sputum samples and were diagnosed with
TB at the study clinic. Considerably more patients than these were
registered for TB treatment at the clinic. The majority of these
additional patients were diagnosed elsewhere but were transferred
to the study clinic to receive treatment. A small group of patients
were started on TB treatment without attempting to produce a
sputum sample, against the diagnostic algorithm in place at the
clinic. These patients were therefore not included in the study.
Conduct of the study in a single, well-researched clinic may also
be considered a limitation. However, differences in the patient
populations served by different clinics suggest that a large number
of clinics would be required if the study were to be conducted
across multiple clinics, and, for this study, it was not logistically or
economically feasible to install on-site laboratories in multiple
smaller clinics. Comparisons before and after the introduction of
new diagnostic algorithms are also subject to confounding by
concurrent changes in practices. Overall, although there were
several limitations with the pragmatic approach chosen in this
study, we believe that the results obtained represent the closest to
those that would be seen under programmatic conditions, while
balancing a comparison with a valid control group. More
interventionist approaches are unlikely to reflect routine practice.
Not surprisingly, the benefits of Xpert testing were particularly
evident among HIV-infected individuals in this study. The HIV
epidemic has had a dramatic impact on TB case notifications in
this region, and tackling HIV-associated TB will be key to
controlling the TB epidemic [14]. HIV infection is associated with
paucibacillary disease, and consequently, sputum smear micros-
copy performs particularly poorly in this patient group [15]. In
Khayelitsha, many patients are diagnosed with TB on clinical
grounds only. Indeed, given the prior lack of a TB diagnostic test
with improved sensitivity in HIV-infected individuals, clinical TB
diagnosis has been the focus of considerable training in the study
clinic over many years prior to this study. Despite this, by 3 wk
after presentation, close to double the proportion of HIV-infected
participants had initiated TB treatment in the Xpert arm
compared to the routine arm, and the proportion who started
treatment without bacteriological confirmation was more than
halved.
More extensive and more rapid treatment initiation might be
expected to reduce mortality, particularly among HIV-infected
patients with low CD4 cell counts. There was, however, no
difference in mortality between study arms, overall or among
HIV-infected individuals. The recent, larger XTEND study, also
in South Africa, similarly found no difference in mortality with
Xpert versus smear microscopy, although, contrary to the current
study, Xpert did not significantly increase the proportion treated
for TB [16]. Unfortunately, data on CD4 cell counts was
inconsistently available, and we were not able to assess mortality
in the subgroup of patients with low CD4 levels, where we might
expect to see the greatest mortality benefit.
Xpert also resulted in limited clinical impact in the TB-NEAT
study [8]. While initial default from treatment was reduced, very
0.
00
0.
10
0.
20
0.
30
0.
40
0.
50
P
ro
po
rti
on
 w
ho
 in
iti
at
ed
 T
B
 tr
ea
tm
en
t
1003 873 833 805 772 727 595 460 382 335Routine
982 759 733 715 698 669 567 374 302 259Xpert
n
0 10 20 30 40 50 60 70 80 90
Days
Figure 3. Proportion of participants initiating TB treatment by time to TB treatment initiation for both study arms, ITT analysis
(p=0.0042). Xpert: solid line; routine: dashed line.
doi:10.1371/journal.pmed.1001760.g003
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AB
Figure 4. Proportion of HIV-infected and -uninfected participants initiating TB treatment by time to treatment initiation for both
study arms, ITT analysis. Xpert: solid line; routine: dashed line. (A) HIV-infected individuals (p,0.001); (B) HIV-uninfected individuals (p= 0.778).
doi:10.1371/journal.pmed.1001760.g004
Impact of Xpert for TB Diagnosis in South Africa
PLOS Medicine | www.plosmedicine.org 9 November 2014 | Volume 11 | Issue 11 | e1001760
high (more than 40%) proportions of patients in both the Xpert
and smear microscopy arms had received treatment by 8 wk, and
there was no difference in TB-related morbidity in that large
multicentre study. The authors postulate that any potential
benefits from Xpert are masked by high levels of rapid empiric
treatment initiation among smear-negative patients [17]. In our
study population, empiric treatment is less common, and there is
greater reliance on culture to subsequently confirm disease. While
the provision of culture for all patients with presumptive TB might
be considered ideal, the delay in receiving results means that most
patients are treated empirically anyway. We may, however, have
underestimated empiric treatment by including only participants
producing sputum samples. Nonetheless, under these conditions,
Xpert significantly reduced the proportion of patients who started
TB treatment without bacteriological confirmation of disease,
while simultaneously increasing the overall proportion starting
treatment. This suggests that with Xpert more of the right patients
initiated treatment.
While there is a high prevalence of microbiologically confirmed
TB in our study population, the yield from sputum smear
microscopy was particularly poor, primarily as most smear
microscopy was conducted in the on-site laboratory. This is in
contrast to previous routine data among the same population,
where microscopy was performed in the central laboratory, and
yield was higher [10]. Although this was a newly established
laboratory, it passed all external quality assessment proficiency
testing, and the laboratory technologist was experienced. This low
microscopy yield reflects the reality of smaller, decentralised
laboratories with a single laboratory technician [18]. Encourag-
ingly, the quality of Xpert testing in this same laboratory was
consistently high [4].
One of the major benefits of the Xpert MTB/RIF test is
expected to be increased case detection for MDR-TB, through
greater access to rifampicin susceptibility testing. No difference in
confirmed rifampicin-resistant TB was found in this current study;
however, the study was not powered to detect such a benefit, and
significant efforts had been made to improve the detection of
rifampicin resistance in this setting prior to this study [19]. One of
the principal benefits of Xpert for patients with rifampicin-
resistant TB will be more rapid treatment initiation, which might
be expected to reduce both early mortality and transmission.
Recent reports have raised concern about false-positive Xpert
results among patients who have been previously treated for TB
[20]. Reassuringly, patients found to be Xpert-positive and
culture-negative were not more common among those who were
previously treated for TB. These results suggest that instances of
false-positive results, although concerning, may be uncommon,
and reinforce the need to interpret all diagnostic tests in the
context of clinical presentation.
While every effort was made to ensure accuracy of follow-up data
to confirm TB treatment initiation and deaths, it is possible that the
data were incomplete, and some participants may have died or
initiated treatment elsewhere without these events being captured in
our data. However, this potential bias is not likely to be different
across the study arms and is therefore not expected to influence the
study conclusions. Another potential limitation is the lack of culture
as the gold standard for TB diagnosis for all participants. However,
the study aimed to assess the impact of Xpert in comparison with
routine practice, and culture is generally available only for a
proportion of those with presumptive TB, or not at all, in high-
burden settings. The provision of culture for all participants would
have, therefore, altered routine practice in this setting.
Controlling the TB epidemic in high-burden settings, particu-
larly those with high HIV prevalence, such as in Khayelitsha, will
require the implementation of new tools and programmes that do
more than just provide incremental benefit over current strategies.
While Xpert is considerably more costly than smear microscopy—
with implementation expected to result in substantially increased
health system costs in the short to medium term—it does offer the
chance to impact TB morbidity and mortality over the long term
[21]. This randomised trial demonstrates that implementation of
Xpert for TB diagnosis in this setting has the potential to improve
both programme and individual outcomes and therefore deliver
the longer term population outcomes promised by modelling
studies [22].
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Editors’ Summary
Background. In 2012, about 8.6 million people developed
active tuberculosis (TB)—a contagious mycobacterial disease
that usually affects the lungs—and at least 1.3 million people
died from the disease. Most of these deaths were in low- and
middle-income countries, and a fifth were in HIV-positive
individuals, who are particularly susceptible to TB. Mycobac-
terium tuberculosis, the bacterium that causes TB, is spread in
airborne droplets when people with active disease cough or
sneeze. The characteristic symptoms of TB include a cough,
weight loss, and night sweats. Diagnostic tests for TB include
microscopic examination of sputum (mucus coughed up
from the lungs), growth (culture) of M. tuberculosis from
sputum, and molecular tests (for example, the automated
Xpert MTB/RIF test) that rapidly and accurately detect M.
tuberculosis in sputum and determine its antibiotic resis-
tance. TB can be cured by taking several antibiotics daily for
at least six months, although the emergence of multidrug-
resistant TB is making the disease harder to treat.
Why Was This Study Done? To improve TB control, active
disease needs to be diagnosed and treated quickly. However,
sputum microscopy, the mainstay of TB diagnosis in many
high-burden settings, fails to identify up to half of infected
people, and mycobacterial culture (the ‘‘gold standard’’ of TB
diagnosis) is slow and often unavailable in resource-limited
settings. In late 2010, the World Health Organization
recommended the routine use of the Xpert MTB/RIF test
(Xpert) for TB diagnosis, and several low- and middle-income
countries are now scaling up access to Xpert in their national
TB control programs. But although Xpert performs well in
ideal conditions, little is known about the impact of its
implementation in routine (real-life) settings. In this prag-
matic cluster-randomized trial, the researchers assess the
health impacts of Xpert in a large TB/HIV primary health care
clinic in South Africa, an upper-middle-income country that
began to scale up access to Xpert for individuals showing
symptoms of TB (individuals with presumptive TB) in 2011. A
pragmatic trial asks whether an intervention works under
real-life conditions; a cluster-randomized trial randomly
assigns groups of people to receive alternative interventions
and compares outcomes in the differently treated ‘‘clusters.’’
What Did the Researchers Do and Find? The researchers
assigned everyone with presumptive TB attending a TB/HIV
primary health care clinic in Cape Town to receive either
Xpert for TB diagnosis or routine sputum microscopy and
limited culture. Specifically, Xpert was requested on the
routine laboratory request forms for individuals attending
the clinic during randomly designated Xpert weeks but not
during randomly designated routine testing weeks. During
the 51-week trial, 982 individuals were assigned to the Xpert
arm, and 1,003 were assigned to the routine testing arm, but
because clinic staff sometimes failed to request Xpert during
Xpert weeks, only 882 participants in the Xpert arm received
the intervention. In an ‘‘intention to treat’’ analysis (an
analysis that considers the outcomes of all the participants in
a trial whether or not they received their assigned
intervention), 13% of bacteriologically confirmed TB cases
in the Xpert arm did not initiate TB treatment by three
months after enrollment (the trial’s primary outcome)
compared to 25% in the routine testing arm. The proportion
of participants with microbiologically confirmed TB and the
proportion initiating TB treatment were higher in the Xpert
arm than in the routine testing arm. Finally, the time to
treatment initiation was lower in the Xpert arm than in the
routine testing arm, particularly among HIV-infected partic-
ipants.
What Do These Findings Mean? These findings show
that, in this primary health care setting, the provision of
Xpert for TB diagnosis in individuals with presumptive TB
provided benefits over testing that relied primarily on
sputum microscopy. Notably, these benefits were seen even
though a substantial proportion of individuals assigned to
the Xpert intervention did not actually receive an Xpert test.
The pragmatic nature of this trial, which aimed to minimize
clinic disruption, and other aspects of the trial design may
limit the accuracy and generalizability of these findings.
Moreover, further studies are needed to discover whether
the use of Xpert in real-life settings reduces the burden of TB
illness and death over the long term. Nevertheless, these
findings suggest that the implementation of Xpert has the
potential to improve the outcomes of TB control programs
and may also improve outcomes for individuals.
Additional Information. Please access these websites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1001760.
N The World Health Organization provides information (in
several languages) on all aspects of tuberculosis, including
general information on tuberculosis diagnostics and
specific information on the roll-out of the Xpert MTB/RIF
test; further information about the World Health Organi-
zation’s endorsement of Xpert MTB/RIF is included in a
Strategic and Technical Advisory Group for Tuberculosis
report; the ‘‘Global Tuberculosis Report 2013’’ provides
information about tuberculosis around the world, includ-
ing in South Africa
N The Stop TB Partnership is working towards tuberculosis
elimination and provides patient stories about tuberculosis
(in English and Spanish); the Tuberculosis Vaccine Initiative
(a not-for-profit organization) also provides personal
stories about tuberculosis
N The US Centers for Disease Control and Prevention has
information about tuberculosis and its diagnosis (in English
and Spanish)
N The US National Institute of Allergy and Infectious Diseases
also has detailed information on all aspects of tuberculosis
N The South African National Tuberculosis Management
Guidelines 2014 are available
N The Foundation for Innovative New Diagnostics, a not-for-
profit organization that helps to develop and introduce
new diagnostic tests for tuberculosis, malaria, and
neglected tropical diseases, has detailed information about
the Xpert MTB/RIF test
N More information about TB, HIV, and drug-resistant TB
treatment in Khayelitsha, Cape Town, South Africa are
provided by Me´decins sans Frontie`res, South Africa
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